St. James Investment Company Investment Adviser’s Q3 2025 Letter
LETTER TO INVESTORS “The essence of strategy is choosing what not to do.” – Michael Porter England experienced a period of strong prosperity in
Curtiss-Wright Stock Still A Buy After A 40% Rally? My Updated Price Target (NYSE:CW)
This article was written by Follow Dhierin-Perkash Bechai is an aerospace, defense and airline analyst. Dhierin runs the investing group The Aerospace Forum, whose
Whirlpool: Stock Likely To Continue Diving – Sell (NYSE:WHR)
This article was written by Follow Always on the hunt for undervalued, promising stocks with a focus on risk and reward. Limited risks and
Weekly Indicators: Almost Completely Unaffected By Government Shutdown (SP500)
This article was written by Follow New Deal democrat As a professional who started an individual investor for almost 30 yeas ago, I quickly
New car down payments hit 4-year low as buyers struggle with affordability challenges
Car shoppers are facing affordability challenges in the market for new vehicles despite average down payments dipping to nearly the lowest level in four
CS Disco: Not A Lot To Like For This Law Software Company (NYSE:LAW)
This article was written by Follow I am a software developer by trade who focuses on finding value in the market wherever it may
POET Technologies Downgraded To Buy, But Along With A Powerful Options Strategy
This article was written by Follow “Fundamental Options” would be the title of my investing style, because I combine fundamental analysis with the power
Viant (DSP): Sell-Off Driven By Temporary Headwinds; Long-Term Thesis Remains Intact
This article was written by Follow An individual investor primarily focused on undercovered companies, with up to 100 companies on my watchlist. My areas
Markets Weekly Outlook – Getting Ready For September NFP Week
This article was written by Follow Dean Popplewell has nearly two decades of experience trading currencies and fixed income instruments. He has a deep
Quince Therapeutics, Inc. – Special Call
Follow Quince Therapeutics, Inc. – Special Call Company Participants Dirk Thye – CEO, Chief Medical Officer & DirectorBrendan Hannah – Chief Business Officer, COO,
Most Read
